Literature DB >> 31784835

Decision tree algorithm in locally advanced rectal cancer: an example of over-interpretation and misuse of a machine learning approach.

Francesca De Felice1, D Crocetti2, M Parisi3, V Maiuri3, E Moscarelli3, R Caiazzo3, N Bulzonetti3, D Musio3, V Tombolini3.   

Abstract

PURPOSE: To analyse the classification performances of a decision tree method applied to predictor variables in survival outcome in patients with locally advanced rectal cancer (LARC). The aim was to offer a critical analysis to better apply tree-based approach in clinical practice and improve its interpretation.
MATERIALS AND METHODS: Data concerning patients with histological proven LARC between 2007 and 2014 were reviewed. All patients were treated with trimodality approach with a curative intent. The Kaplan-Meier method was used to estimate overall survival (OS). Decision tree methods were was used to select important variables in outcome prediction.
RESULTS: A total of 100 patients were included. The 5-year and 7-year OS rates were 76.4% and 71.3%, respectively. Age, co-morbidities, tumor size, clinical tumor classification (cT) and clinical nodes classification (cN) were the important predictor variables to the tree's construction. Overall, 13 distinct groups of patients were defined. Patients aged < 65 years with cT3 disease and elderly patients with a tumor size < 5 cm seemed to have highest rates of survival. But the process over-fitted the data, leading to poor algorithm performance.
CONCLUSION: We proposed a decision tree algorithm to identify known and new pre-treatment clinical predictors of survival in LARC. Our analysis confirmed that tree-based machine learning method, especially classification trees, can be easily interpreted even by a non-expert in the field, but controlling cross validation errors is mandatory to capture its statistical power. However, it is necessary to carefully analyze the classification error trend to chose the important predictor variables, especially in little data. Machine learning approach should be considered the new unexplored frontier in LARC. Based on big datasets, decision trees represent an opportunity to improve decision-making process in clinical practice.

Entities:  

Keywords:  Big data; Chemoradiotherapy; Decision tree; Machine learning; Rectal cancer; Surgery; Survival

Mesh:

Year:  2019        PMID: 31784835     DOI: 10.1007/s00432-019-03102-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  10 in total

1.  Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study.

Authors:  Dexin Jiao; Rui Zhang; Zhiqiang Gong; Fang Liu; Yue Chen; Qinrui Yu; Liping Sun; Hongyan Duan; Shendong Zhu; Fei Liu; Jian Wang; Jianhui Jia
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

2.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.

Authors:  Claus Rödel; Torsten Liersch; Heinz Becker; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Ullrich Graeven; Dirk Arnold; Marga Lang-Welzenbach; Hans-Rudolf Raab; Heiko Sülberg; Christian Wittekind; Sergej Potapov; Ludger Staib; Clemens Hess; Karin Weigang-Köhler; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer
Journal:  Lancet Oncol       Date:  2012-05-23       Impact factor: 41.316

3.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

Authors:  Carlo Aschele; Luca Cionini; Sara Lonardi; Carmine Pinto; Stefano Cordio; Gerardo Rosati; Salvatore Artale; Angiolo Tagliagambe; Giovanni Ambrosini; Paola Rosetti; Andrea Bonetti; Maria Emanuela Negru; Maria Chiara Tronconi; Gabriele Luppi; Giovanni Silvano; Domenico Cristiano Corsi; Anna Maria Bochicchio; Germana Chiaulon; Maurizio Gallo; Luca Boni
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

4.  Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

Authors:  Michael J O'Connell; Linda H Colangelo; Robert W Beart; Nicholas J Petrelli; Carmen J Allegra; Saima Sharif; Henry C Pitot; Anthony F Shields; Jerome C Landry; David P Ryan; David S Parda; Mohammed Mohiuddin; Amit Arora; Lisa S Evans; Nathan Bahary; Gamini S Soori; Janice Eakle; John M Robertson; Dennis F Moore; Michael R Mullane; Benjamin T Marchello; Patrick J Ward; Timothy F Wozniak; Mark S Roh; Greg Yothers; Norman Wolmark
Journal:  J Clin Oncol       Date:  2014-05-05       Impact factor: 44.544

5.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Authors:  Jean-Pierre Gérard; David Azria; Sophie Gourgou-Bourgade; Isabelle Martel-Laffay; Christophe Hennequin; Pierre-Luc Etienne; Véronique Vendrely; Eric François; Guy de La Roche; Olivier Bouché; Xavier Mirabel; Bernard Denis; Laurent Mineur; Jean-François Berdah; Marc André Mahé; Yves Bécouarn; Olivier Dupuis; Gérard Lledo; Christine Montoto-Grillot; Thierry Conroy
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.

Authors:  Francesca De Felice; Daniela Musio; Anna Lisa Magnante; Nadia Bulzonetti; Ilaria Benevento; Rossella Caiazzo; Vincenzo Tombolini
Journal:  Clin Colorectal Cancer       Date:  2016-02-13       Impact factor: 4.481

7.  Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.

Authors:  Xin An; Xi Lin; Feng-Hua Wang; Karyn Goodman; Pei-Qiang Cai; Ling-Heng Kong; Yu-Jing Fang; Yuan-Hong Gao; Jun-Zhong Lin; De-Sen Wan; Zhi-Zhong Pan; Pei-Rong Ding
Journal:  Eur J Cancer       Date:  2012-10-11       Impact factor: 9.162

8.  Neoadjuvant-intensified treatment for rectal cancer: time to change?

Authors:  Daniela Musio; Francesca De Felice; Nadia Bulzonetti; Roberta Guarnaccia; Rossella Caiazzo; Caterina Bangrazi; Nicola Raffetto; Vincenzo Tombolini
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

9.  Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer.

Authors:  Francesca De Felice; Ilaria Benevento; Anna Lisa Magnante; Daniela Musio; Nadia Bulzonetti; Rossella Caiazzo; Vincenzo Tombolini
Journal:  BMC Cancer       Date:  2017-05-12       Impact factor: 4.430

10.  Clinical predictive factors of pathologic complete response in locally advanced rectal cancer.

Authors:  Francesca De Felice; Luciano Izzo; Daniela Musio; Anna Lisa Magnante; Nadia Bulzonetti; Federico Pugliese; Paolo Izzo; Pierfrancesco Di Cello; Pietro Lucchetti; Sara Izzo; Vincenzo Tombolini
Journal:  Oncotarget       Date:  2016-05-31
  10 in total
  2 in total

1.  Synaptophysin, CD117, and GATA3 as a Diagnostic Immunohistochemical Panel for Small Cell Neuroendocrine Carcinoma of the Urinary Tract.

Authors:  Gi Hwan Kim; Yong Mee Cho; So-Woon Kim; Ja-Min Park; Sun Young Yoon; Gowun Jeong; Dong-Myung Shin; Hyein Ju; Se Un Jeong
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

2.  Adoption of Dexmedetomidine in Different Doses at Different Timing in Perioperative Patients.

Authors:  Jing Xie; Shiqiang Feng; Zhenhua Qu
Journal:  Biomed Res Int       Date:  2022-07-15       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.